Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations
Most relevant news about DAIICHI SANKYO COMPANY, LI
01/31Astellas Pharma keeps profit forecast as prostate cancer drug sales rise
RE
01/28DAIICHI SANKYO COMPANY, LIMITED : quaterly earnings release
01/27DAIICHI SANKYO : Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy ..
BU
01/22Roche wins approval for cancer drug Kadcyla in fast-growing China market
RE
01/07DAIICHI SANKYO : ENHERTU Now Available in U.S. for HER2 Positive Unresectable or..
AQ
2019AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer
RE
2019DAIICHI SANKYO : AstraZeneca - Enhertu approved in the US for HER2-positive unre..
AQ
2019DAIICHI SANKYO : ENHERTU Approved in the U.S. for HER2 Positive Unresectable or ..
AQ
2019DAIICHI SANKYO : Enhertu (trastuzumab deruxtecan) approved in the US for HER2-po..
AQ
2019DAIICHI SANKYO : Launches Antitumor Agent Bevacizumab Biosimilar for Intravenous..
AQ
2019ASTRAZENECA : Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in..
AQ
2019Nikkei bounces back on trade deal hopes, steelmakers shine
RE
2019DAIICHI SANKYO : Announces Positive Results from ESAX-DN Phase 3 study in Japan ..
AQ
2019DAIICHI SANKYO : Files Declaratory Judgement Action Related to its Proprietary A..
AQ
2019DAIICHI SANKYO : Announces Transfer from Astellas Pharma of Three Products in As..
AQ
2019Kansai Electric president apologises for payments scandal
RE
2019DAIICHI SANKYO COMPANY, LIMITED : Ex-dividend day for interim dividend
FA
2019Mitsubishi Tanabe Pharma and Daiichi Sankyo announce alliance for ALS treatme..
AQ
2019Trial of Tepco executives over Japan's Fukushima disaster heads to conclusion
RE
2019DAIICHI SANKYO : Announces Launch of Oxycodone Extended Release Tablets NX 'Daii..
AQ
2019AstraZeneca's Tagrisso gets China OK for type of lung cancer
RE
2019GSK builds oncology pipeline as drug shown to help myeloma patients
RE
2019Influenza Vaccines Market is Expected to Surpass USD 6 billion by 2025 | Key ..
AQ
2019MCKESSON : TURALIO FDA Approved Treatment of TGCT, Available at Biologics by McK..
AQ
2019DAIICHI SANKYO : FDA Approves Daiichi Sankyo's TURALIO for the Treatment of Sele..
AQ
2019AstraZeneca raises sales forecast after second quarter cancer drug, China boo..
RE
2019GENERAL ELECTRIC : Daiichi Sankyo to transfer marketing authorization rights for..
AQ
2019DAIICHI SANKYO : Provides Update on FDA Review of Quizartinib for the Treatment ..
AQ
2019DAIICHI SANKYO : VANFLYTA Receives Approval in Japan for the Treatment of Relaps..
AQ
2019DAIICHI SANKYO : Announcement Regarding Recent Media Reports
AQ
2019Daiichi Sankyo looking to sell OTC drug unit for about $900 million - Nikkei ..
RE
2019DAIICHI SANKYO : Announces Update to H5N1 Influenza Vaccine National Project
AQ
2019DAIICHI SANKYO : FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiich..
AQ
2019EXELIXIS' : Collaborator Daiichi Sankyo Launches MINNEBRO Tablets in Japan
AQ
2019DAIICHI SANKYO : Launches 'MINNEBRO Tablets' in Japan
AQ
2019DAIICHI SANKYO : AstraZeneca - Fam trastuzumab deruxtecan demonstrated clinicall..
AQ
2019ASTRAZENECA : Trastuzumab deruxtecan demonstrated clinically
AQ
2019DAIICHI SANKYO : Announcement Regarding Vaccine Quality Testing Methods
AQ
2019ZYMEWORKS : Daiichi Sankyo Selects Lead Candidate Built on Zymeworks' Azymetric ..
AQ
2019DAIICHI SANKYO : Announces Regarding Vaccine Quality Testing Methods
PU
2019DAIICHI SANKYO : Announces the Sale of Its Nihonbashi Building in Japan
PU
2019DAIICHI SANKYO : Launches 'Tarlige Tablets' for Pain Treatment in Japan
AQ
2019DAIICHI SANKYO : Launches “Tarlige® Tablets” for Pain Treatment in J..
PU
2019DAIICHI SANKYO : EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE ..
PU
2019DAIICHI SANKYO : Provides Update on Ongoing FDA Review for Quizartinib for Treat..
PU
2019DAIICHI SANKYO : EMA Validates Daiichi Sankyo's Marketing Authorization Applicat..
PU
2019Cancer Drug Deal Carries High Price -- WSJ
DJ
2019EUROPE : European stocks rise, clocking best quarter in four years
RE
2019LONDON STOCK EXCHANGE : FTSE 100 gains as trade progress offsets latest Brexit s..
RE
2019AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
RE
2019DAIICHI SANKYO : AstraZeneca in cancer deal with Daiichi Sankyo
AQ
2019AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal
RE
2019ASTRAZENECA : AZ and Daiichi Sankyo enter collaboration in novel
AQ
2019DAIICHI SANKYO : to tie up with AstraZeneca on new cancer drug
AQ
2019DAIICHI SANKYO : Announces Chief Executive Officer (CEO) Change
PU
2019DAIICHI SANKYO : and AstraZeneca Announce Global Development and Commercializati..
PU
2019DAIICHI SANKYO : Confirms Plans to Accelerate BLA Submission to U.S. FDA for Tra..
PU
2019DAIICHI SANKYO : Initiates Phase 3 Trial of Mirogabalin in Asian Post-spinal Cor..
PU
2019DAIICHI SANKYO COMPANY, LIMITED : Ex-dividend day for final dividend
FA
2019DAIICHI SANKYO : Anti-epilepsy Drug VIMPAT for I.V. infusion 200mg Launched in J..
AQ
2019DAIICHI SANKYO : Presents Positive Results of the First Randomized, Controlled T..
PU
2019DAIICHI SANKYO : Anti-epilepsy Drug VIMPAT Dry syrup 10% Launched in Japan
AQ
2019DAIICHI SANKYO : Anti-epilepsy Drug VIMPAT® Dry syrup 10% Launched in Japan
PU
2019Japan's Daiichi Sankyo explores OTC drugs business sale, hires JPMorgan -sour..
RE
2019DAIICHI SANKYO : Announces Organizational Restructuring Effective April 1, 2019 ..
PU
2019DAIICHI SANKYO : Appoints New Group Corporate Officers
PU
2019DAIICHI SANKYO : FDA Grants Priority Review for Daiichi Sankyo's New Drug Applic..
PU
2019DAIICHI SANKYO : Announces Transfer of Daiichi Sankyo Propharma Takatsuki Plant ..
PU
2019DAIICHI SANKYO : Initiates Pivotal Phase 3 Trial of Trastuzumab Deruxtecan (DS-8..
PU
2019DAIICHI SANKYO : Mitsubishi UFJ Capital and Tokyo Institute of Technology Announ..
PU
2019DAIICHI SANKYO : Announces Marketing Approval in Japan of “Tarlige® Tablet..
PU
2019DAIICHI SANKYO : Announces Approval of MINNEBRO(TM) Tablets for the Treatment of..
PU
2019DAIICHI SANKYO : Pediatric Dosage and Administration Approved for Anti-epileptic..
PU
2019DAIICHI SANKYO : Europe Enters into European Licensing Agreement with Esperion f..
PU
2018DAIICHI SANKYO : Announces Date for Dissolution of Japan Vaccine and Measures fo..
PU
1  2  3  4  5  6  7Next
Upcoming event on DAIICHI SANKYO COMPANY, LI